OvariGEne – OVAGENE ONCOLOGY

What Role Do Genes Play?

The medications you take rely on internal mechanisms to metabolize and transport them throughout your body. During this process, thousands of protein molecules interact with them and may alter how well they work. This means that your genes may affect how effectively (or ineffectively) you absorb and metabolize a particular drug, which in turn affects how well the drug works for you.

Therefore, the genetic make-up alters the individual’s response to drugs.
While medications may work well for most people, in certain people, a medication may not work or it may cause troublesome side effects. Knowing a patient’s genetic code may, therefore, assists the physician in making an informed treatment decision.

How Does This Affect Cancer Drugs?

In cancer care the need to know whether a drug will or will not work is vitally important, both because these drugs often produce serious side effects and because the time it takes to prove a drug ineffective may allow cancer cells to grow or metastasize.
Pharmacogenomic testing for ovarian cancer

While Platinum therapy has been the primary therapy regimen for ovarian cancer, in recent years the use of combination therapy in first line ovarian cancer has become more prominent, in randomized clinical trials, the combination therapies have demonstrated similar outcomes, so selecting the best therapy based on tumor genetics may lead to tumor improvement in care and outcome.

By reducing adverse drug responses, improving efficacy, and ensuring each patient gets the drug they are most likely to respond to, pharmacogenomics testing in ovarian cancer helps deliver the most appropriate therapy.

Each person’s cancer and response to treatment is unique.

Assessment of an individual patient’s predisposition to drugs is essential to achieve the goal of personalized medicine in cancer therapy. CerviGENE Test from Ovagene Oncology uses genomic technology to understand the effects of all relevant genes on the behaviour of a drug or conversely the effect of a drug on gene expression.

OvariGENE™ Molecular Drug Response/Recurrence Profile

Molecular diagnostic assay that identify key genes associated with chemotherapy resistance in ovarian cancer patients.

OvariGENE contains biomarkers for each of the drugs recommended by the NCCN Guidelines for use in recurrent ovarian cancer. The OvariGENE results can be used in combination with the patient’s clinical data to prioritize the therapy selection based on the genetics of an individual’s tumor, thus improving outcome and lowering the costs and side effects of ineffective therapies.

Through such prioritization, the patient should receive a therapy to which they are more likely to respond, thus improving outcome and lower the costs and side effects of ineffective therapies.

Kay’s Array™ Targeted Therapies Panel

Quantitative gene expression assay that examines the protein expression of selected gene associated with response to a variety of targeted drugs. The assay is clinically useful in the treatment of late stage and recurrent ovarian cancer since there is a broader list of therapeutic options to consider including targeted therapies.

Key Opinion Leaders thoughts from USA on Ovagene Gynecologic Panels:
“Ovagene as a whole offers excellence science, professional interactions, timely analysis and data output and has been a great supporter of women diagnosed with gynecologic malignancies. It has been a pleasure to work with them over the past year and it is our hope that we can help them further validate all of their hard work. Patients have been very eager to get information about Ovagene, how it works and trying to get further answers abouth the potential biology of their cancers. This then leading to the potential of choosing better, more well-suited theraphy for their disease and hopefully better survivals.”

1

Veronica L. Schimp. D.O. FACOG
Chief, Gynecology Oncology
MD Anderson Cancer Center Orlando

“We have worked with OvaGene for two years. OvaGene offers timely, efficient services, and provide critical information for helping decisions for our patients. We are pleased to support OvaGene’s growth and the key role they play in gynecologic cancer patient care.”

2

Jonathan M. Lancaster, MD PhD
President, Moffitt Medical Group
Chair, Department of Women’s Oncology
Moffitt Cancer Center

“Ovagene Oncology has been in the forefront of molecular diagnostics for gynecologic cancer, a field that is just now unfolding as we explore options for truly personalized oncology care for women with gynecologic cancer. Given that most women with ovarian cancer suffer recurrennce of disease, and that only a fraction of drugs have activity for an individual tumor, along with interest in new targeted (and also very expensive) therapies, it becomes imperative that we improve a patient’s odds for response to theraphy through study of the patient’s own unique tumor gene signatures. Ovagene’s clinical performance with quick turnaround and telephone support for diagnostic assistance have been exemplary.”

3

Robert Holloway. MD
Co-Director of Gynecologic Oncology
Florida Hospital Cancer Institute
Professor of OB-Gyn, University of Central Florida

Tab content
Tab content

WE WOULD LOVE TO HEAR FROM YOU

Contact us